Brexanolone caprilcerbate

A medication used for the treatment of postpartum depression

Brexanolone caprilcerbate
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Brexanolone caprilcerbate is a medication primarily used in the treatment of postpartum depression (PPD). It is a novel formulation of the neuroactive steroid brexanolone, which is a synthetic form of the naturally occurring hormone allopregnanolone. This medication is administered intravenously and is specifically designed to address the unique hormonal changes that occur during the postpartum period.

Mechanism of Action

Brexanolone caprilcerbate acts as a positive allosteric modulator of the gamma-aminobutyric acid (GABA) A receptor. GABA is the primary inhibitory neurotransmitter in the central nervous system, and its modulation is crucial for maintaining neurotransmission balance. By enhancing the effects of GABA, brexanolone caprilcerbate helps to stabilize mood and reduce symptoms of depression.

Pharmacokinetics

Brexanolone caprilcerbate is administered via a continuous intravenous infusion over a period of 60 hours. This method of administration ensures a steady concentration of the drug in the bloodstream, allowing for effective modulation of GABA_A receptors. The drug is metabolized in the liver and excreted primarily through the kidneys.

Clinical Use

Brexanolone caprilcerbate is specifically indicated for the treatment of moderate to severe postpartum depression in adult women. The treatment is typically administered in a controlled healthcare setting due to the need for continuous monitoring of the patient during the infusion process.

Side Effects

Common side effects of brexanolone caprilcerbate include dizziness, somnolence, and headache. Due to the potential for excessive sedation and loss of consciousness, patients are monitored closely during treatment. There is also a risk of hypoxia and hypotension, necessitating the availability of supportive care.

Regulatory Status

Brexanolone caprilcerbate was approved by the Food and Drug Administration (FDA) for the treatment of postpartum depression in 2019. It represents a significant advancement in the management of PPD, offering a rapid onset of action compared to traditional antidepressants.

Related Pages

• Postpartum depression
• Allopregnanolone
• GABA_A receptor
• Neurotransmitter